louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05877404: Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer
Official title: Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Endometrial Cancer
Keywords: Genetic testing
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2023-05-26
Enrollment: 112
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Gynecologic Oncologists and gynecologic oncology fellows-in-training from around the world, who are members of the Society of Gynecologic Oncology (SGO).

Brief summary: In order to formulate strategies to improve adherence to best practice guidelines, as well as utilization of novel therapies, investigators must understand current practice patterns surrounding tumor genetic testing in endometrial cancer. The aim is to survey a representative sample of gynecologic oncologists who belong to the society of gynecologic oncology, via an email survey, to better understand current practices surrounding tumor genetic testing as well as determine if there have been any changes to practice since the publication of recent trials on the use of immune-checkpoint inhibitors in endometrial cancer.

Detailed description: Primary Objective: Proportion of physicians reporting the use of different tumor genetic testing strategies among newly diagnosed endometrial cancer patients.

Secondary Objectives:

* Explore the use of informed consent in tumor genetic testing in endometrial cancer
* Explore clinician confidence in utilizing tumor genetic testing to guide treatment decisions.
* Explore the impact of recent publications regarding immunotherapy on the use of tumor genetic testing in endometrial cancer.

Eligibility criteria: Inclusion Criteria:

* Member of the Society of Gynecologic Oncology
* Gynecologic Oncologist or Gynecologic Oncology Fellow-in-Training

Primary outcomes:
measure: Percentage of providers reporting the use of different tumor genetic testing strategies among newly diagnosed endometrial cancer patients
timeFrame: 4 months
Secondary outcomes:
measure: Frequency of providers using different strategies of informed consent in tumor genetic testing in endometrial cancer
timeFrame: 4 months
measure: Number of providers reporting confidence in utilizing tumor genetic testing to guide treatment decisions
timeFrame: 4 months
measure: Number of providers who change their counseling or testing strategies for endometrial cancer
timeFrame: 4 months
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Wake Forest Baptist Comprehensive Cancer Center
state: North Carolina
Study officials:
affiliation: Wake Forest Baptist Comprehensive Cancer Center
name: Kathryn Weaver, PhD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06087601: The Impact of Genicular Nerves Chemical Neurolysis on the Quality of Life of Patients with Advanced Knee Osteoarthritis.
Official title: The Impact of Genicular Nerves Chemical Neurolysis on the Quality of Life of Patients with Advanced Knee Osteoarthritis. a Randomized, Double-blinded, Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Osteo Arthritis Knee
Osteoarthritis
Lead sponsor: Poznan University of Medical Sciences
Sponsor class: OTHER
First posted: 2023-10-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 110
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Group 1: sham blocks Group 2: genicular nerve neurolysis
Primary purpose: TREATMENT

Brief summary: Genicular nerves chemical neurolysis in advanced osteoarthritis of the knee joint.

Detailed description: The study aims to assess the safety and effectiveness of regional pain treatment methods and their impact on the quality of life of patients with advanced osteoarthritis of the knee joint.

Eligibility criteria: Inclusion Criteria:

* Patients of the Pain Treatment Clinic of the Transfiguration of Jesus Clinical Hospital of the Medical University of Poznań will be qualified for the study
* patients with gonarthrosis who failed to achieve satisfactory pain control (NRS\>3) despite the use of NSAIDs, Paracetamol, and co-analgesics
* Age of patients: from 18 to 110 years of age.
* Caucasian patients can give informed, complete, written consent.

Exclusion Criteria:

* suspected or diagnosed opioid dependence syndrome
* active cancer
* dementia

Primary outcomes:
measure: NRS
timeFrame: 7 days after procedure
measure: NRS
timeFrame: 30 days after procedure
measure: NRS
timeFrame: 3 months after procedure
measure: NRS
timeFrame: 6 months after procedure
Secondary outcomes:
measure: Health Questionnaire (EQ-5D-5L)
timeFrame: 7 days after surgery
measure: Health Questionnaire (EQ-5D-5L)
timeFrame: 30 days after surgery
measure: Health Questionnaire (EQ-5D-5L)
timeFrame: 3 months after surgery
measure: Health Questionnaire (EQ-5D-5L)
timeFrame: 6 months after surgery
measure: neurological deficits
timeFrame: 7 days after procedures
measure: neurological deficits
timeFrame: 30 days after procedures
measure: neurological deficits
timeFrame: 3 months after procedures
measure: neurological deficits
timeFrame: 6 months after procedures
measure: total opioid consumption
timeFrame: 7 days after procedure
measure: total opioid consumption
timeFrame: 30 days after procedure
measure: total opioid consumption
timeFrame: 3 months after procedure
measure: total opioid consumption
timeFrame: 6 months after procedure
Other outcomes:
Locations:
city: Poznan
country: Poland
facility: Poznan University of Medical Sciences
state: Poznań
Study officials:
affiliation: Poznań University of Medical Sciences
name: Katarzyna Wieczorowska-Tobis, Prof.dr hab
role: STUDY_DIRECTOR
References:
Clinical trial NCT01974401: Effect of Supragingival Irrigators Containing Chlorhexidine on Oral Health in Blood Dyscrasia
Official title: Effect of Using Supragingival Irrigators Containing Chlorhexidine on Oral Health in Patients With Blood Dyscrasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Severe Neutropenia
Thrombocytopenia
Chemotherapy
Blood Dyscrasia Patients
Keywords: oral irrigator
leukemia
blood dyscrasia
Oral Health Index Simplified (OHI-S)
supra gingival irrigator
Lead sponsor: Mashhad University of Medical Sciences
Sponsor class: OTHER
First posted: 2013-11-01
Enrollment: 20
Sex: ALL
Minimum age (years): 12
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: in this study , effectiveness of supragingival irrigators containing chlorhexidine is compared with routine oral health measures in patients with blood dyscrasia whom can not use effective oral health measures(e.g brushing ) due to their systemic condition(e,g,neutropenia ,thrombocytopenia,..)

Detailed description: Since some patients with hematologic malignancies cannot brush effectively and are at increased risk of bleeding and infection due to severe neutropenia and thrombocytopenia we want to access whether a none invasive method ( water jet systems containing chlorhexidine ) Can help this patients to get better oral health indexes in comparison with routine oral health measures in these type of patients.

Eligibility criteria: Inclusion Criteria:

patients with a blood dyscrasia, severe neutropenia and thrombocytopenia, absence of periodontitis, absence of any oral mucosal lesion in onset of study, patient consent

Exclusion Criteria:

diabetes mellitus, observation of any side effect (resulted from the device), severe oral mucositis in intervention group(grade 3 and4 WHO), edentulousness, intolerance of device in severely malaise patients, patient death

Primary outcomes:
measure: improvement in oral health status
timeFrame: 3 weeks
Secondary outcomes:
measure: incidence of oral mucositis
timeFrame: 3 weeks
Other outcomes:
Locations:
city: Mashhad
country: Iran, Islamic Republic of
facility: Oral Medicine Department of Mashhad dental School,Oral and Maxillofacial diseases research center
state: Khorasan Razavi
Study officials:
affiliation: Oral and maxilloifacial diseases research center of Mashhad university of medical sciences
name: Pegah Mosannen Mozafari, assistant professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04724304: Myocardial Blood Volume Measurement by Real-Time Myocardial Perfusion Echocardiography Correlates to Myocardial Compressibility by Cardiac Magnetic Resonance Imaging in Healthy Subjects
Official title: Myocardial Blood Volume Measurement by Real-Time Myocardial Perfusion Echocardiography Correlates to Myocardial Compressibility by Cardiac Magnetic Resonance Imaging in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Adults
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-01-26
Enrollment: 115
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: This study is being done to find out the normal amount of blood within the heart muscle and the variations in this blood flow between a cardiac MRI and TTE.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years.
* Available for testing performed in Rochester, MN.
* Willing to undergo both an echocardiogram with RTMPE and CMR.
* Study subject providing consent.

Exclusion Criteria:

* Adults \< 18 years.
* BMI \<30 kg/m\^2.
* Hypertension.
* Diabetes Mellitus.
* Stroke.
* Cardiomyopathy or structural heart disease.
* Known coronary artery disease or history of myocardial infarction.
* Contraindication to echo enhancement agent or gadolinium administration such as an allergy.
* Renal GFR \< 50 mL/mL.
* Females who are pregnant.
* Subject unwilling to consent.

Primary outcomes:
measure: Myocardial blood volume
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo clinic Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Courtney Bennett, D.O.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00048204: A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
Official title: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients With Major Depressive Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Depressive Disorder, Major
Keywords: Depression
Psychiatry
Major Depressive Disorder
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2002-10-30
Enrollment: 372
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Placebo Controlled Study Evaluating Efficacy And Safety of Medication In Patients With Major Depressive Disorder (MDD)


Eligibility criteria: Inclusion Criteria:

* Patients meet the diagnosis of Major Depressive Disorder (MDD).

Exclusion Criteria:

* Patients with a primary diagnosis other than MDD.
* Patients with a history of schizophrenia, schizoaffective disorders, seizure disorders or bipolar affective disorder.
* Patients receiving formal psychotherapy or cognitive/behavioral therapy concurrently or in the 12 weeks prior to screening visit.
* Patient is actively suicidal.
* Patients who have a history of migraine headaches.

Primary outcomes:
measure: Hamilton Depression Rating Scale
timeFrame: 8 Weeks
Secondary outcomes:
measure: Hamilton Depression Rating Scale Clinical Global Impression-Global Improvement Clinical Global Impression-Severity of Illness Hospital Anxiety and Depression Scale
timeFrame: 8 Weeks
Other outcomes:
Locations:
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT05352204: Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas
Official title: The Guiding Value of Tumor Micronecrosis for Using Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carcinoma, Hepatocellular
Keywords: hepatocellular carcinoma
TACE
tumor necrosis
Lead sponsor: Zhejiang University
Sponsor class: OTHER
First posted: 2022-04-28
Enrollment: 900
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: From June 2014 to April 2018, HCC patients who underwent liver resection in our center were retrospectively reviewed.

Brief summary: Micronecrosis is a novel pathological feature of hepatocellular carcinoma (HCC). This study was aimed at evaluating the effect of tumor micronecrosis on postoperative transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinomas, and further exploring the value of micronecrosis for guiding TACE in HCC management.


Eligibility criteria: Inclusion Criteria:

* (1) pathologically confirmed HCC (2) achievement of R0 resection.

Exclusion Criteria:

* (1) simultaneous presence of other tumors ; (2) receipt of preoperative anti-tumoral treatments; (3) concurrent treatment with other antitumoral therapies in combination with TACE; (4) tumor necrosis that could be observed by gross examination; (5) a lack of necessary preoperative laboratory test results.

Primary outcomes:
measure: overall survival
timeFrame: after liver resection until June 1, 2020
Secondary outcomes:
measure: disease-free survival
timeFrame: after liver resection until June 1, 2020
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: the First Affiliated Hospital, School of Medicine, Zhejiang University
state: Zhejiang
city: Hangzhou
country: China
facility: the First Affiliated Hospital, Zhejiang University School of Medicine
state: Zhejiang
Study officials:
References:
Clinical trial NCT00837304: Colon Capsule Endoscopy Versus Standard Colonoscopy in Ulcerative Colitis
Official title: Colon Capsule Endoscopy Versus Standard Colonoscopy in Assessing Disease Activity in Patients With Ulcerative Colitis - A Prospective Trial
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Ulcerative Colitis
Lead sponsor: University Hospital Muenster
Sponsor class: OTHER
First posted: 2009-02-05
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with known ulcerative colitis

Brief summary: The dimension of diagnostic procedures and therapy of chronic inflammatory bowel diseases largely depends on the degree of mucosal inflammation. Video colonoscopy is currently the gold standard in the evaluation of the mucosa in patients with Ulcerative Colitis (UC). PillCam Colon Capsule was developed by Given Imaging, Israel, as possible alternative imaging modality to evaluate mucosal changes in patients with UC. The colonic mucosa can be visualized and recorded by video while the colon capsule passes the colon.

Many patients suffering from UC ask their physician for possible alternative diagnostic imaging because they are uncomfortable with conventional colonoscopy.

The primary aim of the present study is to compare the new Pillcam Colon Capsule with standard colonoscopy with respect to assessing mucosal disease activity and localization of inflamed colonic mucosa in patients with known UC.


Eligibility criteria: Inclusion Criteria:

* Patients over 18 years of age with
* known ulcerative colitis
* Indication for Standard Colonoscopy
* Informed Consent given by the patient

Exclusion Criteria:

* Patient has dysphagia
* Patient has congestive heart failure
* Patient has renal insufficiency
* Patient is known or is suspected to suffer from intestinal obstruction
* Patient has a cardiac pacemaker or other implanted electronical medical devices
* Patient is pregnant
* Patient has had prior abdominal surgery of the GI tract
* Patient has any condition, which precludes compliance with study and/or device instructions.
* Age less than 18

Primary outcomes:
measure: a) disease activity of ulcerative colitis (modified Rachmilewitz score) b) extent of colonic manifestation of ulcerative colitis c) accuracy parameters (sensitivity, specificity)
timeFrame: 12 months
Secondary outcomes:
measure: a) patient comfort b) detection of polyps c) differences in recognition of disease activity (physicians, nurses) d) differences in findings in the group of physicians (inter-observer differences)
timeFrame: 12 months
Other outcomes:
Locations:
city: Muenster
country: Germany
facility: University of Muenster, Dept. of Medicine B
Study officials:
affiliation: University of Muenster, Dept. of Medicine B
name: Tobias Meister, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00826501: Randomized Trial Comparing Endoscopy and Surgery for Pancreatic Cyst-gastrostomy
Official title: Randomized Trial Comparing Endoscopy and Surgery for Pancreatic Cyst-gastrostomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pancreatic Pseudocysts
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2009-01-22
Enrollment: 40
Sex: ALL
Minimum age (years): 19
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with pancreatitis can develop inflammatory fluid collection around the pancreas called pseudocysts. Pseudocysts may cause abdominal pain when they are more than 6cm in size. These pseudocysts can be treated (drained) by surgery or by endoscopy. Both treatment options are the current standard-of-care at all institutions around the World. The aim of this study is to identify the better of the two techniques, surgery versus endoscopy, for treatment of patients with pancreatic pseudocysts. This will be done by comparing a) the rates of pseudocyst recurrence b) quality of life of patients following treatment and c) cost associated with treatment, between both treatment modalities.

Detailed description: The purpose of this study is to examine endoscopic ultrasound guided celiac plexus neurolysis (CPN) with analgesic therapy in patients with unresectable pancreatic cancer will decrease the severity of abdominal pain when compared to analgesic therapy alone. The specific primary aim of this study is to evaluate the efficacy of EUS-CPN + analgesic therapy (Group 1) in pain relief of patients with unresectable pancreatic cancer when compared with analgesic therapy (Group 2). The hypothesis will be tested by comparing the changes in reported pain severity between those who receive EUS-CPN in addition to analgesic therapy as compared to analgesic therapy alone.

Eligibility criteria: Inclusion Criteria:

* age \> 19yrs
* able to provide informed consent
* pancreatic pseudocyst by CT

Exclusion Criteria:

* age \< 19yrs
* unable to consent
* pancreatic abscess or necrosis

Primary outcomes:
measure: Compare median time to pseudocyst recurrence between patients undergoing EUS or Surgical Cysto-gastrostomy
timeFrame: 24 months
Secondary outcomes:
measure: Quality of Life following treatment which will be assessed on a 3-month basis for 24-months using the SF-36 questionnaire
timeFrame: 24 months
measure: Median time to pseudocyst recurrence at 24 month follow-up.
timeFrame: 24 months
Other outcomes:
measure: Compare pain medication usage
timeFrame: 24 months
Locations:
city: Birmingham
country: United States
facility: University of Alabama at birmingham
state: Alabama
Study officials:
References:
citation: Varadarajulu S, Bang JY, Sutton BS, Trevino JM, Christein JD, Wilcox CM. Equal efficacy of endoscopic and surgical cystogastrostomy for pancreatic pseudocyst drainage in a randomized trial. Gastroenterology. 2013 Sep;145(3):583-90.e1. doi: 10.1053/j.gastro.2013.05.046. Epub 2013 May 31.
Clinical trial NCT00036101: Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Bipolar Disorder
Keywords: Bipolar I Disorder
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor class: INDUSTRY
First posted: 2002-05-09
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to learn if aripiprazole is effective for the treatment of patients with acute symptoms of Bipolar disorder.


Eligibility criteria: Inclusion Criteria:

Patients with acute symptoms of Bipolar Disorder

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tuscaloosa
country: United States
facility: Local Institution
state: Alabama
city: Little Rock
country: United States
facility: Local Institution
state: Arizona
city: Beachwood
country: United States
facility: Local Institution
state: California
city: Chula Vista
country: United States
facility: Local Institution
state: California
city: Riverside
country: United States
facility: Local Institution
state: California
city: San Clemente
country: United States
facility: Local Institution
state: California
city: San Diego
country: United States
facility: Local Institution
state: California
city: Stanford
country: United States
facility: Local Institution
state: California
city: Washington
country: United States
facility: Local Institution
state: District of Columbia
city: North Miami
country: United States
facility: Local Institution
state: Florida
city: Winter Park
country: United States
facility: Local Institution
state: Florida
city: Honolulu
country: United States
facility: Local Institution
state: Hawaii
city: Chicago
country: United States
facility: Local Institution
state: Illinois
city: Indianapolis
country: United States
facility: Local Institution
state: Indiana
city: Louisville
country: United States
facility: Local Institution
state: Kentucky
city: Belmont
country: United States
facility: Local Institution
state: Massachusetts
city: Newton Center
country: United States
facility: Local Institution
state: Massachusetts
city: New Baltimore
country: United States
facility: Local Institution
state: Michigan
city: Lawrence
country: United States
facility: Local Institution
state: New York
city: Butner
country: United States
facility: Local Institution
state: North Carolina
city: Cincinnati
country: United States
facility: Local Institution
state: Ohio
city: Medina
country: United States
facility: Local Institution
state: Ohio
city: Philadelphia
country: United States
facility: Local Institution
state: Pennsylvania
city: Austin
country: United States
facility: Local Institution
state: Texas
city: Houston
country: United States
facility: Local Institution
state: Texas
city: Falls Church
country: United States
facility: Local Institution
state: Virginia
city: Bellevue
country: United States
facility: Local Institution
state: Washington
Study officials:
References: